Compare PCB & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCB | CADL |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.0M | 339.8M |
| IPO Year | N/A | 2021 |
| Metric | PCB | CADL |
|---|---|---|
| Price | $22.45 | $6.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $24.50 | $19.43 |
| AVG Volume (30 Days) | 20.6K | ★ 731.5K |
| Earning Date | 01-27-2026 | 03-12-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 43.50 | N/A |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $107,743,000.00 | N/A |
| Revenue This Year | $21.55 | N/A |
| Revenue Next Year | $8.65 | N/A |
| P/E Ratio | $9.12 | ★ N/A |
| Revenue Growth | ★ 13.61 | N/A |
| 52 Week Low | $16.00 | $4.25 |
| 52 Week High | $24.04 | $13.68 |
| Indicator | PCB | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 54.72 |
| Support Level | $21.75 | $5.91 |
| Resistance Level | $23.21 | $6.62 |
| Average True Range (ATR) | 0.57 | 0.36 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 34.74 | 55.25 |
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.